Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 3,728,738
- Estimated value
- $37,212,805
- Report date
- 10 Jun 2024
- Price
- $9.98
- Ownership
- By ARCH Venture Fund XII, L.P.
ARCH Venture Partners XII, LLC - 10%+ Owner at Rapport Therapeutics, Inc.
Issuer-level insider activity
- Role
- 10%+ Owner
- Issuer ticker
- RAPP on Nasdaq
- Entity type
- Company
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
No buys or sells have been reported by ARCH Venture Partners XII, LLC since 14 Aug 2025
Reported holdings for ARCH Venture Partners XII, LLC in Rapport Therapeutics, Inc.
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Series A Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 10 Jun 2024
- Price
- Ownership
- By ARCH Venture Fund XII, L.P.
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 10 Jun 2024
- Price
- Ownership
- By ARCH Venture Fund XII, L.P.
- Underlying class
- Common Stock
- Underlying amount
Transaction history for ARCH Venture Partners XII, LLC in Rapport Therapeutics, Inc.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.